The partnership will combine RetinAI’s discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases to identify additional, novel biomarkers and predictors of disease progression
RetinAI partners with Boehringer Ingelheim. (Credit: Swapnil Potdar on Unsplash)
Switzerland-based RetinAI Medical has teamed up with German pharmaceutical company Boehringer Ingelheim to improve patient outcomes for people with geographic atrophy (GA).
The partnership combines RetinAI’s discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases.
RetinAI’s AI tools which are used for identifying novel biomarkers will be tested for the analysis of Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence.
It will help identify additional, novel biomarkers and predictors of disease progression.
The combination of advanced digital technologies and AI will help develop new treatments, enable early diagnosis of retinal diseases and prevent vision loss and blindness, said the Swiss firm.
RetinAI CEO Carlos Ciller said: “RetinAI is excited to embark on this very important collaboration with Boehringer Ingelheim, a leader in the development of innovative, more precise treatments and application of digital technologies in retinal diseases.
“Our Discovery platform and novel AI tools in GA accelerate research and provide robust disease insights.
“We are confident that this collaboration with Boehringer Ingelheim can pave the way to novel treatments that are better tailored to a patient’s disease to transform the lives of people living with retinal diseases.”
Established in 2017, RetinAI is engaged in developing AI software solutions that advance clinical, research and pharmaceutical workflows using machine learning and computer vision.
The company builds software tools that collect, organise and analyse health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare.
Its global team international team leverages its clinical, technical, and scientific expertise to support the transition from reactive to preventive medicine for severe eye diseases.
The company’s data management platform and models, including AI models for GA progression prediction, analyse large-scale datasets to gain a deep understanding of outcomes.
GA is a progressive, advanced form of age-related macular degeneration (AMD) and a major cause of complete loss of sight, worldwide.